GANX - NASDAQ
Gain Therapeutics, Inc.
$1.86
+3.9%Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
At a Glance
Live Snapshotganx
Net Change in Cash
Last Annual Value
10.46M
3-Year CAGR
33%
5-Year CAGR
8%
10-Year CAGR
46%
Gain Therapeutics, Inc. Competitors Analysis of Net Change in Cash
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Gain Therapeutics, Inc. NASDAQ:GANX | 10.46M | 32.6% | -18.7% | N/A | |
 Fortress Biotech, Inc. NASDAQ:FBIO | 21.79M | N/A | -21.5% | N/A | |
 CervoMed Inc. NASDAQ:CRVO | 1.21M | -31.2% | -42.3% | N/A | |
 Lite Strategy, Inc. NASDAQ:LITS | 14.31M | 130.6% | N/A | N/A | |
 Clene Inc. NASDAQ:CLNN | -6.97M | N/A | N/A | N/A | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | -54.26M | N/A | N/A | N/A | |
 Immix Biopharma, Inc. NASDAQ:IMMX | 76.25M | 165.5% | 34.6% | N/A | |
 PMV Pharmaceuticals, Inc. NASDAQ:PMVP | -2.89M | N/A | N/A | N/A | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 21.97M | N/A | N/A | N/A | |
 Vaxart, Inc. NASDAQ:VXRT | 28.59M | N/A | 11.1% | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 6.35M | N/A | -24.4% | N/A |
Gain Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your GANX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.